Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Am J Physiol Heart Circ Physiol. 2022 Jul 1;323(1):H89-H99. doi: 10.1152/ajpheart.00091.2022. Epub 2022 Apr 22.
Hemorrhage is a leading cause of preventable battlefield and civilian trauma deaths. Low-dose (i.e., an analgesic dose) morphine is recommended for use in the prehospital (i.e., field) setting. Morphine administration reduces hemorrhagic tolerance in rodents. However, it is unknown whether morphine impairs autonomic cardiovascular regulation and consequently reduces hemorrhagic tolerance in humans. Thus, the purpose of this study was to test the hypothesis that low-dose morphine reduces hemorrhagic tolerance in conscious humans. Thirty adults (15 women/15 men; 29 ± 6 yr; 26 ± 4 kg·m, means ± SD) completed this randomized, crossover, double-blinded, placebo-controlled trial. One minute after intravenous administration of morphine (5 mg) or placebo (saline), we used a presyncopal limited progressive lower-body negative pressure (LBNP) protocol to determine hemorrhagic tolerance. Hemorrhagic tolerance was quantified as a cumulative stress index (mmHg·min), which was compared between trials using a Wilcoxon matched-pairs signed-rank test. We also compared muscle sympathetic nerve activity (MSNA; microneurography) and beat-to-beat blood pressure (photoplethysmography) during the LBNP test using mixed-effects analyses [time (LBNP stage) × trial]. Median LBNP tolerance was lower during morphine trials (placebo: 692 [473-997] vs. morphine: 385 [251-728] mmHg·min, < 0.001, CI: -394 to -128). Systolic blood pressure was 8 mmHg lower during moderate central hypovolemia during morphine trials (post hoc = 0.02; time: < 0.001, trial: = 0.13, interaction: = 0.006). MSNA burst frequency responses were not different between trials (time: < 0.001, trial: = 0.80, interaction: = 0.51). These data demonstrate that low-dose morphine reduces hemorrhagic tolerance in conscious humans. Thus, morphine is not an ideal analgesic for a hemorrhaging individual in the prehospital setting. In this randomized, crossover, placebo-controlled trial, we found that tolerance to simulated hemorrhage was lower after low-dose morphine administration. Such reductions in hemorrhagic tolerance were observed without differences in MSNA burst frequency responses between morphine and placebo trials. These data, the first to be obtained in conscious humans, demonstrate that low-dose morphine reduces hemorrhagic tolerance. Thus, morphine is not an ideal analgesic for a hemorrhaging individual in the prehospital setting.
出血是可预防的战场和民用创伤死亡的主要原因。推荐在院前(即现场)环境中使用低剂量(即镇痛剂量)吗啡。吗啡的使用可降低啮齿动物的出血耐受性。然而,尚不清楚吗啡是否会损害自主心血管调节,从而降低人类的出血耐受性。因此,本研究的目的是检验低剂量吗啡是否会降低清醒人体的出血耐受性。
30 名成年人(15 名女性/15 名男性;29±6 岁;26±4kg·m,平均值±SD)完成了这项随机、交叉、双盲、安慰剂对照试验。静脉注射吗啡(5mg)或安慰剂(生理盐水)1 分钟后,我们使用预晕厥有限进展性下肢负压力(LBNP)方案来确定出血耐受性。出血耐受性通过累积应激指数(mmHg·min)来量化,通过 Wilcoxon 配对符号秩检验比较试验间的差异。我们还使用混合效应分析[时间(LBNP 阶段)×试验]比较 LBNP 试验期间的肌肉交感神经活动(MSNA;微神经记录)和逐搏血压(光电容积描记法)。吗啡试验期间的 LBNP 耐受中位数较低(安慰剂:692[473-997] vs. 吗啡:385[251-728]mmHg·min,<0.001,CI:-394 至-128)。吗啡试验期间中度中心性低血容量时的收缩压低 8mmHg(事后检验 = 0.02;时间:<0.001,试验:=0.13,交互作用:=0.006)。试验间 MSNA 爆发频率反应无差异(时间:<0.001,试验:=0.80,交互作用:=0.51)。
这些数据表明,低剂量吗啡可降低清醒人体的出血耐受性。因此,吗啡在院前环境中并不是出血个体的理想镇痛剂。在这项随机、交叉、安慰剂对照试验中,我们发现低剂量吗啡给药后对模拟出血的耐受性降低。在吗啡和安慰剂试验之间,MSNA 爆发频率反应无差异的情况下,观察到这种出血耐受性的降低。这些数据是首次在清醒人体中获得的,表明低剂量吗啡降低了出血耐受性。因此,吗啡在院前环境中并不是出血个体的理想镇痛剂。